Mesothelioma | Mesothelioma

... CBD - Press Release Center for Biological Diversity BECAUSE LIFE IS GOOD Protecting endangered species and wild places through science, policy, education, and environmental law.

Center for Biological Diversity Bluewater Network Court Rejects Bush Administration Attempt to DelayAlternative Fuels Vehicles Purchase Plan for Federal and Private Fleets Action Urgently Needed to Reduce Dependence on Oil, Lessen Global Warming and Cut Air Pollution Contacts:Peter Galvin, Center for Biological Diversity, (520) 907-1533 Jeff Miller, Center for Biological Diversity (510) 499-9185 Danielle Fugere, Bluewater Network, a Div.

of Friends of the Earth, (415) 544-0790 x15 Jay Tutchton, Esq., University of Denver, College of Law, (303) 871-6034 FOR IMMEDIATE RELEASE: March 31, 2006 San Francisco, Calif.

– Following an earlier March 6th ruling finding the U.S.

Department of Energy (“DOE”) in violation of its obligations under the Energy Policy Act of 1992, District Court Judge William Alsup yesterday rejected further government delay and ordered the DOE to come into compliance with the Act within 2 years.

The Energy Policy Act (“Act”), passed in the wake of the first Gulf War, is designed to reduce dependence on foreign oil, lessen global warming and cut air pollution by mandating the purchase of alternative fuels vehicles (“AFV”s).

In the ruling earlier this month, the Court rejected a DOE finding that federal agencies cannot take action to reduce ...

... Scotsman.com News - Health - Innovative scanner to pinpoint patients' exact needs @import "http://www.scotsman.com/css/network_banner_strict.css"; @import "http://www.scotsman.com/css/common.css"; @import "http://news.scotsman.com/css/screen.css?

nocache=20051111"; @import "http://multimedia.scotsman.com/css/colours/6699cc.css"; @import "http://multimedia.scotsman.com/css/colours/003300.css"; @import "http://multimedia.scotsman.com/css/colours/003399.css"; @import "http://multimedia.scotsman.com/css/colours/660066.css"; @import "http://multimedia.scotsman.com/css/colours/996600.css"; @import "http://multimedia.scotsman.com/css/colours/0000cc.css"; @import "http://multimedia.scotsman.com/css/colours/000066.css"; @import "http://multimedia.scotsman.com/css/colours/9999cc.css"; @import "http://multimedia.scotsman.com/css/colours/330000.css"; @import "http://multimedia.scotsman.com/css/colours/990000.css"; @import "http://multimedia.scotsman.com/css/colours/666699.css"; Please note: Your browser has been unable to load the stylesheet that accompanies this page.

The page is still readable.

[Accessibility statement] [Skip to navigation] Websites Scotsman.com websites News Sport Business The Scotsman Scotland on Sunday Edinburgh Evening News Dating Jobs Motors Property Business Finder Member Centre Web Feeds Media Pack Site Help Digital Archive 1817-1950 Photo Gallery Reader Holidays Scotsman Calendar Money Fantasy Golf Haggis Hunt Edinburgh Festivals Heritage & Culture Living Wea...

...Advertisement The primary objective of this open-label study is to demonstrate an improvement in overall survival.

Secondary objectives are evaluation of safety, overall response rate, time to progression, and progression free survival.

Relapsed or refractory non-small cell Patients who meet all eligibility criteria will receive Talotrexin (PT-523) on a 21-day cycle.

Myelosuppresion and mucositis were the dose limiting toxicities of the preceding phase I portion of the trial that determined the recommended phase II dose of Talotrexin in this setting.

"Antifolates clearly have a role in the management of advanced non-small cell These preliminary data are encouraging and support taking this drug into the phase II setting," said Dr Jennifer Garst, assistant professor of medicine at Duke University, and an investigator on the trial commented.

RELATED NEWS Hana initiates trials of oral spray14 Dec 2005 GlaxoSmithKline: Zofran sales set for off-Par performance22 Nov 2005 Hana initiates trial of talotrexin in leukemia patients13 May 2005 Hana Biosciences initiates trial of anticancer compound9 Sep 2005 Hana Biosciences receives $159,000 for cancer drug studies9 Aug 2005 COMPANIES MENTIONED No companies found YOUR OPINION...